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Summary : We report a case of necrobiotic xanthogranuloma in a 51 year-old white male patient 
presenting with a 6-year history of multiple indurated violaceous nodules and plaques involving the 
eyelids, trunk and extremities. He had an associated paraproteinemia (Ig G lambda), elevated 
sedimentation rate, cryoglobulinemia and hypocomplementemia. No extracutaneous involvement was 
detected. He was successfully treated with chlorambucil (2 mg/d for 7 months), leading to 
disappearance of all skin lesions.
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ARTICLE
Necrobiotic xanthogranuloma (NXG) with paraproteinemia was first described as a distinct clinical entity 
in 1980 by Kossard and Winkelmann [1]. Before that, cases of atypical multicentric reticulohistiocytosis 
with paraproteinemia [2], atypical xanthoma disseminatum [3] or atypical forms of necrobiosis lipoidica 
diabeticorum [4], could be possible cases of NXG. Approximately 60 cases of NXG have been reported 
since then, most associated with Ig G monoclonal gammopathy but with an unclear causal relationship. 
Cutaneous lesions are typically yellow-red to violaceous nodules and plaques, characteristically 
involving the periorbital area, face, trunk and extremities. 
We report a case of a patient with a long standing disease without extracutaneous involvement, that 
responded positively to low-dose chlorambucil. 
Case report 
Disease presentation 
A 51 year-old male white farmer had a 6-year history of multiple firm violaceous papulonodules on the 
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trunk and arms. The patient was otherwise asymptomatic. Dermatological examination revealed about 
20 red to violaceous plaques (Fig. 1) in an asymmetric distribution, on the neck and trunk (the biggest 
one at the right supraclavicular area, 12 cm long). The smallest lesions were red-brown nodules on the 
limbs. Some plaques showed a central yellow-red colour, with telangiectasias and xanthomatization. A 
0.8 cm diameter nodule was noted on the left inferior eyelid. Xanthelasma on the eyelids and periferical 
nerve enlargement were also observed. The rest of the physical examination was normal. 
Cutaneous histopathological findings 
Three cutaneous biopsies of different lesions were performed. A prominent feature in all biopsy 
specimens was the presence of a histiocytic infiltrate and aggregated epithelioid cells from the middle 
dermis through subcutis. There were numerous multinucleated giant cells, which were frequently of the 
Touton type, foam cells and atypical foreign body giant cells (Fig. 2). Two specimens contained focal 
areas of cholesterol clefts and hyaline necrobiosis marginated from the surrounding granuloma (Fig. 3). 
Laboratory findings 
Laboratory examination revealed elevated sedimentation rate (119 mm/hr, normal < 10 mm/hr) and B2 
microglobulin (3,438 ng/ml, normal < 1,900 ng/ml); platelets and total white blood cell counts were below 
normal (platelets = 123 x 103/µl; WCC = 3.30 x 103/µl; differential count: 36.3% lymphocytes, 49% 
neutrophils); haemoglobin was normal (14.1 g/dl); protein electrophoresis showed a monoclonal 
gammopathy of the Ig G lambda type (Ig G = 3,160 mg/dl, normal 793-1,590 mg/dl). Bence-Jones 
proteins were not recovered in urine. Iliac crest bone marrow aspirate revealed a normocellular marrow 
with 4% plasma cells (76% of which showed an abnormal imunophenotype: CD38+, CD 138+, CD56+, 
CD19-) and bone marrow biopsy showed 5 to 10% lambda monoclonal plasma cells. Serum lipids 
(triglycerides = 112 mg/dl, normal 40-160 mg/dl; total cholesterol = 125 mg/dl, normal < 200 mg/dl), liver 
tests, creatinine and glucose tolerance test were normal. There was cryoglobulinemia (372 mcg/ml, 
normal < 40 mcg/ml) Ig A, Ig G and Ig M type, without monoclonality or rheumatoid factor activity. The 
complement profile revealed subnormal levels of C1q (1 mg/dl, normal 12.4-19 mg/dl), C4 (3 mg/dl, 
normal 12-42 mg/dl) and CH50 (classic pathway 8.0 U/ml, normal >19.2 U/ml; alternative pathway 1.4 U/
ml, normal > 2.8 U/ml), but elevation of C3d (1.140 mg/dl, normal < 0.55 mg/dl). Levels of C3 (139 mg/
dl, normal 81-167 mg/dl) and esterase inhibitor C1 (36.9 mg/dl, normal 31.9-38.5 mg/dl) were normal. 
Extracutaneous disease study 
Chest and skeletal x-ray films were normal; chest-abdominal-pelvic CT scan showed homogeneous 
splenomegaly (150 mm), without other alterations. Electrocardiogram and echocardiogram were normal. 
Clinical ophthalmological examination did not reveal abnormalities. 
Nerve biopsy showed a demyelinating neuropathy, without acid-fast bacilli or granulomas. 
Treatment 
The patient was treated with low dose chlorambucil (2 mg/day) for 7 months, resulting in progressive 
flattening of the lesions (Fig. 4), with eventual disappearance of all skin lesions. The paraprotein spike 
has persisted unmodified during all the treatment and follow-up of the patient. There was no 
complication with treatment, and no recurrence in 9 months of follow-up. 
Discussion 
Necrobiotic xanthogranuloma is characterized by peculiar clinical and histopathological findings (Table 
I). It appears to have no sex predilection and the average age of appearance is 56 years (range 17 to 85 
years) [5]. Skin lesions usually occur on the head (frequently the periorbital region), trunk and 
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extremities. Early lesions are indurated red to violaceous papules or nodules, that enlarge to plaques 
with a xanthomatous color. Infiltrated plaques may show telangiectasias and central clearing or atrophy, 
with ulceration [5]. The clinical appearance of the lesions observed in our patient was very typical, but 
ulceration was not observed. 
Typical history consists of a granulomatous dermal and subcutaneous infiltrate with histiocytes, foam 
cells, Touton and foreign body giant cells; a hyaline necrobiosis and cholesterol clefts [6]. All of these 
findings were present in our case. In spite of typical histopathologic features of NXG, Mehregan and 
Winkelmann recommend three biopsy specimens from separate lesions in different locations [5]. 
Various reports have documented the association with extracutaneous involvement including the eye 
(conjunctivitis, keratitis, scleritis, episcleritis, iritis, uveitis, glaucoma, ptosis, ectropion, cataracts), upper 
respiratory tract (presenting hoarseness or painful nodules), granulomatous infiltration of the lung, 
skeletal muscle, kidney, hepatic and splenic granulomas, necrobiotic lesions of the intestine, pelvic and 
retroperitoneal xanthogranuloma lesions [5, 7]. Some authors have advised cardiac evaluation because 
of the presence of myocardial NXG lesions in autopsies [7]. There was no extracutaneous involvement 
in our case. 
According to Mehregan and Winkelmann, 80% of patients with NXG tested with protein electrophoresis 
were found to have paraproteinemia [5], 10% of which had multiple myeloma [1], without an obvious 
correlation between the severity of the hematological disease and the skin lesions [8]. Our patient had 
paraproteinemia but did not have evidence of myeloma. 
The demyelinating neuropathy documented by nerve biopsy was probably also related to 
paraproteinemia. 
Other associated laboratory abnormalities (Table I) have included: elevated sedimentation rate, 
anaemia, leukopenia, abnormal glucose tolerance test, cryoglobulinemia and hypocomplementemia 
(reduced CH50, C1q, C2, C4 and C1 inhibitor). Lipids may be elevated, normal or reduced. Many of 
these laboratory abnormalities were seen in our case. 
The etiopathogenesis of NXG is unknown. Lipoprotein profile described in the literature of NXG are quite 
distinct and their relationship to XNG aetiology is not known. Our patient is normolipemic. Circulating 
immunoglobulins may be complexed with lipids and deposit in the skin and produce a foreign-body 
granulomatous reaction [9]. Complement abnormalities may contribute to immune-complex formation 
[10]. More recently a new possible pathogenesis of NXG was postulated: the activation of monocytes in 
vivo may contribute to the intracellular accumulation of lipoprotein-derived lipids and marked 
hypocholesterolemia [11]. 
Although there is no definitive specific therapy for NXG, alkylating agents (such as chlorambucil or 
melphalan) with or without glucocorticoids have been reported to induce remission of skin lesions. 
Resistant patients or those with severe side effects from this treatment may be subjected to other 
approaches [1] like plasmapheresis [12] or recombinant interferon alfa 2 b [13] (Table I). Treatment with 
chlorambucil in our case led to total remission of the skin lesions but his paraproteinemia remained 
unmodified.
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